The expression of TMED3 was compared between low (Stage I and II) and high stage (Stage III and IV) ccRCC patients in the TCGA and ICGC cohorts, and between low (Grade I and II) and high grade (Grade III and IV) ccRCC patients from the TCGA cohort. Here, TMED3 is linked to nonpapillary renal cell carcinoma.